Arthrosi Therapeutics’ pozdeutinurad is in Phase 3 testing as a treatment for uncontrolled gout. Sobi says this once-daily capsule complements its own asset, an infused biologic medicine currently under FDA review as a third-line gout treatment.
The post Sobi Grows Its Gout Drug Prospects With $950M Acquisition of Startup Arthrosi Therapeutics appeared first on MedCity News.
